Valuation: Neuland Laboratories Limited

Market Cap 250B 2.62B 2.3B 2.12B 1.96B 3.72B 3.78B 25.35B 9.94B 123B 9.85B 9.64B 426B P/E 2026
42.3x
P/E 2027 * 59.7x
Enterprise Value 250B 2.62B 2.29B 2.12B 1.96B 3.72B 3.78B 25.34B 9.93B 123B 9.84B 9.63B 426B EV / Sales 2026
7.59x
EV / Sales 2027 * 11x
Free-Float
62.24%
Yield 2026
0.28%
Yield 2027 * 0.07%
1 day+3.53%
1 week+3.93%
Current month+4.77%
1 month+15.09%
3 months+38.92%
6 months+31.76%
Current year+28.50%
1 week 18,400
Extreme 18400
20,072
1 month 16,569.95
Extreme 16569.95
20,072
Current year 11,500
Extreme 11500
20,072
1 year 11,500
Extreme 11500
20,072
3 years 2,871.4
Extreme 2871.4
20,072
5 years 965.85
Extreme 965.85
20,072
10 years 247.3
Extreme 247.3
20,072
Manager TitleAgeSince
Chief Executive Officer 46 01/04/2026
Director of Finance/CFO - 23/11/2022
Chief Tech/Sci/R&D Officer - 01/03/2023
Director TitleAgeSince
Director/Board Member - 01/08/2025
Director/Board Member 80 31/10/2022
Director/Board Member 82 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+3.53%+3.93%+67.20%+530.24% 2.53B
-0.32%-0.06%+54.17%+167.72% 1,084B
-1.27%-1.65%+65.53%+62.18% 634B
-2.08%-4.61%+30.64%+85.17% 447B
+0.18%-1.76%+29.04%+26.48% 330B
-6.22%-8.14%+28.87%+31.18% 295B
-1.27%-2.91%+27.42%+44.91% 285B
-0.93%-3.57%-27.74%-39.70% 218B
-1.32%-2.83%+22.60%+61.77% 199B
+0.75%+2.65%+19.00%+78.03% 169B
Average -0.90%+2.31%+31.67%+104.80% 366.24B
Weighted average by Cap. -1.25%+2.48%+38.69%+84.13%

Financials

2026 2027 *
Net sales 17.64B 185M 162M 149M 138M 262M 266M 1.79B 700M 8.66B 694M 679M 30B 23.09B 242M 212M 195M 181M 343M 348M 2.34B 916M 11.34B 908M 888M 39.27B
Net income 2.57B 26.95M 23.58M 21.74M 20.12M 38.18M 38.82M 260M 102M 1.26B 101M 98.99M 4.38B 4.21B 44.1M 38.58M 35.58M 32.92M 62.48M 63.52M 426M 167M 2.07B 166M 162M 7.16B
Net Debt -117M -1.22M -1.07M -985K -911K -1.73M -1.76M -11.79M -4.62M -57.21M -4.58M -4.48M -198M 2.94B 30.77M 26.92M 24.83M 22.97M 43.6M 44.33M 297M 117M 1.44B 116M 113M 5B
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
1,794
Date Price Change Volume
09/07/26 19,519.45 +3.53% 3,876
08/07/26 ₹18,854.00 -0.29% 2,572
07/07/26 ₹18,908.70 +0.26% 1,093
06/07/26 ₹18,858.95 -0.30% 976
03/07/26 ₹18,916.45 -0.35% 21,846
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
19,519.45INR
Average target price
21,222.00INR
Spread / Average Target
+8.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NEULANDLAB Stock